PHLDB2

Across TCGA pan-cancer cohorts, PHLDB2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PHLDB2 data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher PHLDB2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated PHLDB2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and KIRP show a favorable association.

KIRC, HNSC, and STAD are the cancer types where PHLDB2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.706	0.554	<.001	167	view →
HNSC	DFS	Quartile	III,IV	0.220	0.616	.002	73	view →
STAD	OS	Quartile	All	0.505	0.692	.002	65	view →
MESO	OS	Median	II,III,IV	0.287	0.490	.003	52	view →
UVM	DFS	Quartile	All	0.293	0.727	.001	29	view →
COAD	DFS	Median	All	0.737	0.824	.004	25	view →
KIRP	DFS	Median	IV	0.765	0.042	.003	19	view →
BLCA	DFS	Tertile	All	0.223	0.527	.010	18	view →
LUAD	DFS	Tertile	IV	0.345	0.721	.022	18	view →
ESCA	OS	Tertile	All	1.000	0.489	.011	17	view →
SARC	OS	Tertile	All	0.854	0.609	.002	7	view →
DLBC	DFS	Median	All	0.599	0.924	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PHLDB2–KIRC (OS)

Open the KIRC breakdown →